SAZYGLIP-M TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus (to improve blood glucose control along with diet and exercise).

This is likely a combination of an antidiabetic DPP-4 inhibitor (commonly saxagliptin/teneligliptin/vildagliptin/linagliptin) with metformin. The DPP-4 inhibitor increases incretin levels to enhance glucose-dependent insulin release and reduce glucagon, while metformin decreases hepatic glucose production and improves insulin sensitivity.

Take exactly as prescribed by your doctor. Usually taken orally once or twice daily with meals (especially if it contains metformin) to reduce stomach upset; swallow tablets whole with water. Do not stop or change dose without medical advice.

Nausea, vomiting, diarrhea, abdominal discomfort, loss of appetite, headache, dizziness, nasopharyngitis, hypoglycaemia (especially with other antidiabetics)

Confirm exact salts/strengths before dispensing as brand composition is unclear. Use with caution in kidney or liver disease; metformin-containing products may rarely cause lactic acidosis (seek urgent care for rapid breathing, severe weakness, abdominal pain). Monitor blood glucose and HbA1c regularly. Risk of hypoglycaemia increases if used with insulin or sulfonylureas. Inform doctor if you have pancreatitis history, heart failure, or are scheduled for contrast imaging/surgery (metformin may need temporary stoppage).

Alcohol (increases risk of hypoglycaemia and lactic acidosis with metformin), insulin and sulfonylureas (increased hypoglycaemia), iodinated contrast media (metformin—risk of lactic acidosis; may need temporary discontinuation), cimetidine (may increase metformin levels), corticosteroids/diuretics (may raise blood glucose), ACE inhibitors (may enhance glucose-lowering effect)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Istamet Tablet, Galvus Met Tablet, Jalra-M Tablet, Kombiglyze XR Tablet, Glycomet GP Tablet